Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Patisiran: Dose Ranging Studies

Standard response letter on patisiran phase 1 and phase 2 dose ranging studies.

Vutrisiran: Use in Patients with Heart Transplant

Standard response letter on the use of vutrisiran in patients who have received a heart transplant.

Patisiran: Pregnancy and Lactation

Standard response letter on patisiran and pregnancy & lactation. This letter contains information on preclinical toxicology studies and the APOLLO, APOLLO-B, and HELIOS-A studies.

Vutrisiran: Use in Patients with Renal Impairment

Standard response letter on vutrisiran and use in patients with renal impairment.

Vutrisiran: Use in Patients with Wild-Type ATTR

Standard response letter on the use of vutrisiran in patients with wild-type ATTR.

Baseline Characteristics of Patients with ATTR Amyloidosis Enrolled into the ConTTRibute Registry

Mivelsiran: cAPPricorn-1 Study

Standard response letter on mivelsiran and the phase 2 cAPPricorn-1 study in patients with sporadic or hereditary CAA.

Patisiran: Cardiac Results from the APOLLO Study

Standard response letter on patisiran and the exploratory cardiac results in the APOLLO study, a study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.

Givosiran: Renal Effects

Standard response letter on renal effects observed with the use of givosiran.

APOLLO-B, a Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis: Primary Long-term Results from the Open-label Extension Period

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.